International audienceBackground: To assess the impact of unstudied societal factors for neovascular age-related macular degeneration (nAMD) on functional outcomes after anti-VEGFs.Methods: Charts of 94 nAMD patients treated in the Monticelli-Paradis Centre, Marseille, France, were reviewed. Phone interviews were conducted to assess societal factors, including transportation, living status, daily reading and social security scheme (SSS). Primary outcome was the impact of family support and disease burden on functional improvement in nAMD.Results: Between baseline and month 24 (M24), 42.4% of the variability in best-corrected visual acuity (BCVA) was explained by the cumulative effect of the following societal factors: intermittent out-patie...
Purpose:To investigate the incidence, characteristics and baseline predictors of poor visual outcome...
Objective To assess the overall effectiveness of anti-vascular endothelial growth factor (VEGF) ther...
The use of anti-vascular endothelial growth factor (VEGF) agents has profoundly changed the prognosi...
Abstract Background To assess the impact of unstudied societal factors for neovascular age-related m...
Objective - To prospectively explore the following patient-reported outcome measures (PROMs) in the ...
To prospectively explore the following patient-reported outcome measures (PROMs) in the management o...
Purpose: To evaluate anti-VEGF treatment patterns and the influence of patient demographic and clini...
Background/aims: Quantitative data regarding the impact of neovascular age-related macular degenerat...
Objective To assess the overall effectiveness of anti-vascular endothelial growth factor (VEGF) ther...
Objective: To describe vision-related quality of life (VRQoL) in a Norwegian population of patients ...
Objective To assess the overall effectiveness of anti-vascular endothelial growth factor (VEGF) ther...
PURPOSE: To assess the impact of disease activity on clinical outcomes in a "real-world" cohort with...
Kimberly L Spooner,1,2 Cleopatra T Mhlanga,1 Thomas H Hong,1 Geoffrey K Broadhead,1 Andrew A Chang1,...
Objective To assess the overall effectiveness of anti-vascular endothelial growth factor (VEGF) ther...
Objective To assess the overall effectiveness of anti-vascular endothelial growth factor (VEGF) ther...
Purpose:To investigate the incidence, characteristics and baseline predictors of poor visual outcome...
Objective To assess the overall effectiveness of anti-vascular endothelial growth factor (VEGF) ther...
The use of anti-vascular endothelial growth factor (VEGF) agents has profoundly changed the prognosi...
Abstract Background To assess the impact of unstudied societal factors for neovascular age-related m...
Objective - To prospectively explore the following patient-reported outcome measures (PROMs) in the ...
To prospectively explore the following patient-reported outcome measures (PROMs) in the management o...
Purpose: To evaluate anti-VEGF treatment patterns and the influence of patient demographic and clini...
Background/aims: Quantitative data regarding the impact of neovascular age-related macular degenerat...
Objective To assess the overall effectiveness of anti-vascular endothelial growth factor (VEGF) ther...
Objective: To describe vision-related quality of life (VRQoL) in a Norwegian population of patients ...
Objective To assess the overall effectiveness of anti-vascular endothelial growth factor (VEGF) ther...
PURPOSE: To assess the impact of disease activity on clinical outcomes in a "real-world" cohort with...
Kimberly L Spooner,1,2 Cleopatra T Mhlanga,1 Thomas H Hong,1 Geoffrey K Broadhead,1 Andrew A Chang1,...
Objective To assess the overall effectiveness of anti-vascular endothelial growth factor (VEGF) ther...
Objective To assess the overall effectiveness of anti-vascular endothelial growth factor (VEGF) ther...
Purpose:To investigate the incidence, characteristics and baseline predictors of poor visual outcome...
Objective To assess the overall effectiveness of anti-vascular endothelial growth factor (VEGF) ther...
The use of anti-vascular endothelial growth factor (VEGF) agents has profoundly changed the prognosi...